MarketWatch: Pfizer beat earnings but here’s why this analyst downgraded the stock to neutral
Mizuho Securities says the pharma giant needs its pipeline to deliver for investors to gain more comfort with Pfizer’s outlook.
We have detected that you are using extensions to block ads. Please support us by disabling these ads blocker.